- Dopaminergic drugs
- Anti-cholinergic drugs
- GABA Agonists
- Anti Convulsants
Cervical Dystonia Management Market size was valued at USD 114.1 million in 2022. It is expected to reach USD 160.6 million by 2029 at a CAGR of 5.0% from 2023-2029. Cervical dystonia, also known as spasmodic torticollis, rare neurological disorder that originates in the brain. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head. The severity of cervical dystonia can vary, but the disorder can cause significant pain and discomfort as well as difficulty due to the abnormal postures. It can affect the quality of life and activities of daily living including employment. Cervical dystonia typically begins in middle age, and rarely begins in adolescence and young adulthood. The cause of cervical dystonia is unknown, although a genetic susceptibility is thought to underlie some cases. According to the Association of neurological American Surgeons about 250,000 people are having cervical dystonia every year. According to National organization for rare diseases (NORD) it is anticipated that around 60,000 individuals in US are suffering with cervical dystonia.
Cervical Dystonia Management Market Key Developments:
- In March, 2019, Ipsen Biopharmaceuticals Inc., the Canadian affiliate of Ipsen has received Health Canada approval for DYSPORT THERAPEUTIC (abobotulinumtoxinA) to treat cervical dystonia.
- In 2019, Merz Pharmaceuticals received USFDA approval fo Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm.
Global Cervical Dystonia Management Market Summary
Study Period
2023-29
Base Year
2022
CAGR
5%
Largest Market
Asia-Pacific
Fastest Growing Market
North-America
Cervical Dystonia Management Market Dynamics
The major driving factors for the market for cervical dystonia market is increase in aging population across the globe. Females are more likely to be get affected by cervical dystonia. Besides this increase in treatment for cervical dystonia and improvement in infrastructure provided fuel for the growth of the market. Furthermore, low and increase in cost of treatment is the major cause for restraining the growth of cervical dystonia market.
North-America Got Significant Share of
Cervical Dystonia Management Market Regional Analysis
On a regional basis, global cervical dystonia management market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The market is dominated by North America due to developed infrastructure, governmental initiatives, and increase in demand for the better treatment of cervical dystonia driving factor in North America. Furthermore, increase in aging population in Canada fuelling the growth of North America cervical dystonia market. Europe and Asia-Pacific accounts to have significant market share. However, Asia-Pacific expected to dominate the market in the forecast period due to continuous development and increase in cervical dystonia treatment procedures. Furthermore, large patient pool in Asia-Pacific region contributes significant growth for cervical dystonia market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The cervical dystonia management market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Cervical Dystonia Management Market Segmentation
By Drug class
By Route Administration
- Oral
- Intravenous
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Others
Frequently Asked Questions
The cervical dystonia management market size was valued at USD 114.1 million in 2022
AbbVie Inc. Adamas Pharmaceuticals, Inc. Allergan plc F. Hoffmann-La Roche Ltd. Ipsen Biopharmaceuticals, Inc.
The cervical dystonia management market segments are by administration, drug class and distribution channel
| 1.Executive Summary |
| 2.Global Cervical Dystonia Management Market Introduction |
| 2.1.Global Cervical Dystonia Management Market - Taxonomy |
| 2.2.Global Cervical Dystonia Management Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Route Of Administration |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Cervical Dystonia Management Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Cervical Dystonia Management Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Cervical Dystonia Management Market By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Dopaminergic drugs |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Anti-cholinergic drugs |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. GABA Agonists |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Anti Convulsants |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Cervical Dystonia Management Market By Route Of Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Intravenous |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Cervical Dystonia Management Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Hospital pharmacies |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail pharmacies |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Cervical Dystonia Management Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Cervical Dystonia Management Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Dopaminergic drugs |
| 9.1.2.Anti-cholinergic drugs |
| 9.1.3.GABA Agonists |
| 9.1.4.Anti Convulsants |
| 9.2. Route Of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Intravenous |
| 9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital pharmacies |
| 9.3.2.Retail pharmacies |
| 9.3.3.Others |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Cervical Dystonia Management Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Dopaminergic drugs |
| 10.1.2.Anti-cholinergic drugs |
| 10.1.3.GABA Agonists |
| 10.1.4.Anti Convulsants |
| 10.2. Route Of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Intravenous |
| 10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital pharmacies |
| 10.3.2.Retail pharmacies |
| 10.3.3.Others |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 10.4.7. |
| 11.Asia Pacific (APAC) Cervical Dystonia Management Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Dopaminergic drugs |
| 11.1.2.Anti-cholinergic drugs |
| 11.1.3.GABA Agonists |
| 11.1.4.Anti Convulsants |
| 11.2. Route Of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Intravenous |
| 11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital pharmacies |
| 11.3.2.Retail pharmacies |
| 11.3.3.Others |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Cervical Dystonia Management Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Dopaminergic drugs |
| 12.1.2.Anti-cholinergic drugs |
| 12.1.3.GABA Agonists |
| 12.1.4.Anti Convulsants |
| 12.2. Route Of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Intravenous |
| 12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital pharmacies |
| 12.3.2.Retail pharmacies |
| 12.3.3.Others |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Cervical Dystonia Management Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Dopaminergic drugs |
| 13.1.2.Anti-cholinergic drugs |
| 13.1.3.GABA Agonists |
| 13.1.4.Anti Convulsants |
| 13.2. Route Of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Intravenous |
| 13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital pharmacies |
| 13.3.2.Retail pharmacies |
| 13.3.3.Others |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.AbbVie Inc. |
| 14.2.2.Adamas Pharmaceuticals, Inc. |
| 14.2.3.Allergan plc |
| 14.2.4.F. Hoffmann-La Roche Ltd. |
| 14.2.5.Ipsen Biopharmaceuticals, Inc. |
| 14.2.6.Jubilant Cadista Pharmaceuticals Inc. |
| 14.2.7.Medtronic plc |
| 14.2.8.Merz Pharma GmbH & Co. KGaA |
| 14.2.9.Mylan N.V. |
| 14.2.10.Revance Therapeutics, Inc. |
| 14.2.11.Solstice Neurosciences, LLC |
| 14.2.12.Sun Pharmaceutical Industries Ltd. |
| 14.2.13.Teva Pharmaceutical Industries Ltd. |
| 14.2.14.US WorldMeds, LLC |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- AbbVie Inc.
- Adamas Pharmaceuticals, Inc.
- Allergan plc
- F. Hoffmann-La Roche Ltd.
- Ipsen Biopharmaceuticals, Inc.
- Jubilant Cadista Pharmaceuticals Inc.
- Medtronic plc
- Merz Pharma GmbH & Co. KGaA
- Mylan N.V.
- Revance Therapeutics, Inc.
- Solstice Neurosciences, LLC
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- US WorldMeds, LLC